Novartis Japan company information, Employees & Contact Information

Novartis taps Argo again, inks potential $5.2B collaboration BioWorld MedTech

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases PR Newswire

Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint BioSpace

Argo Biopharma Announces New Deal With Novartis For Novel Molecules For Cardiovascular Diseases Nasdaq

Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin Fierce Biotech

JP Morgan 2025: Novartis streamlines its portfolio to drive future growth Pharmaceutical Technology

KYORIN and Novartis Forge Global License Agreement for KRP-M223 TipRanks

Kyorin offers Novartis timely new weapon in urticaria The Pharma Letter

Novartis to mass produce next-generation cancer drugs in Japan Nikkei Asia

Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment BioSpace

J.P. Morgan Healthcare Conference 2024 Novartis

Novartis's Japan Unit Faces Criminal Probe for Hypertension Drug Marketing Science | AAAS

U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug Reuters

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia Novartis

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Novartis

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab Novartis

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death Novartis

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 Novartis

Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA) Novartis

Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines Novartis

Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease Novartis

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU Novartis

Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments Novartis

US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent Reuters

Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma Novartis

Novartis Looking for Constructive Ways To Bring Down Drug Costs in US BioSpace

BeiGene-Novartis gastric cancer drug succeeds in late-stage trial Reuters

Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd Novartis

Sun Pharma, Novartis co-opt the copay offer to promote knockoffs of pricey brands Fierce Pharma

Novartis follows brand offloading trend, selling drugs in Japan to Sun Fierce Pharma

Novartis, other investors try to delay sale of Proteus Digital Health Fierce Healthcare

Judge in Japan lets Novartis off the hook in advertising scandal Fierce Pharma

Novartis, Amgen in dispute over migraine drug partnership Reuters

Zolgensma from Novartis receives Japan regulatory approval Pharmaceutical Technology

Aspen alert! Novartis buys assets for $330m in Japan boost BioProcess International

Patent case: Novartis Pharmaceuticals Corporation. v. Accord Healthcare, Inc., USA Wolters Kluwer

Sun Pharma expands presence in Japan with $293 million deal for Novartis drugs BioPharma Dive

Propeller Health, Novartis Co-Package Asthma Medication in Europe for Prescription HIT Consultant

Propeller's digital inhaler tech to be co-prescribed with Novartis' new asthma med Fierce Biotech

Novartis' Zolgensma faces EU, Japan delays after regulators raise 'manufacturing questions' Fierce Pharma

Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate Fierce Biotech

Novartis Japan unit under scrutiny BBC

After TIGIT divorce, Novartis returns tislelizumab to BeiGene as PD-1 gains first European nod Fierce Pharma

Swiss pharma firms plot different paths to blockbuster drugs The Japan Times

Novartis: Reimagining medicine in Japan through innovation The Japan Times

Being there: Amgen and Novartis roll out first ad campaign for migraine drug Aimovig Fierce Pharma

Novartis Diovan scandal claims two more papers Retraction Watch

Novartis Europharm Ltd withdraws its applications for an extension of the indication for Exelon and Prometax (rivastigmine) European Medicines Agency

Novartis co-leads Euthymics A round - Global Corporate Venturing

Korean brokerage firm to buy Novartis campus in Paris for $454 mn: report The Korea Economic Daily Global Edition

Actavis UK Ltd v Novartis AG, Court of Appeal, 17 February 2010 Wolters Kluwer

Japan files criminal complaint against pharma giant worldfinance.com

Abusive patenting: Novartis & Co are using their “evergreening” p... Public Eye

Novartis, Pfizer, Sanofi: How India's pharma GCCs transformed from back office to innovation powerhouse Times of India

Novartis research scrutinised in Japan SWI swissinfo.ch

Sun Pharma acquires Novartis brands in Japan BusinessLine

NHS to lose out on new drugs, pharma firm Novartis warns BBC

Novartis acquiring US firm Avidity Biosciences for $12 bn Tuko News